Ad
ATRC - AtriCure Stock Trading
About | AtriCure Inc. (NASDAQ:ATRC)
Not available
Quote | AtriCure Inc. (NASDAQ:ATRC)
| Last: | $43.25 |
|---|---|
| Change Percent: | 0.78% |
| Open: | $43.46 |
| Close: | $43.25 |
| High: | $43.5 |
| Low: | $42.25 |
| Volume: | 354,925 |
| Last Trade Date Time: | 10/02/2023 03:00:00 am |
News | AtriCure Inc. (NASDAQ:ATRC)
-
2023-09-04 12:21:00 ET Needham sees the medtech sector growing by 7% in 2023 versus 5.7% last year, despite slowed growth in Q2, helped by double-digit growth in certain cardiology categories. The investment bank noted that medtech growth slowed slightly in Q2, expanding by only 8.3% co...
-
2023-08-29 22:32:23 ET Summary AtriCure stock has been heavily sold off following its Q2 numbers, despite strong performance and a revised full-year outlook. The company has seen growth across all segments, with around 20% growth and profits posted at the adj. EBITDA line. Val...
Message Board Posts | AtriCure Inc. (NASDAQ:ATRC)
| Subject | By | Source | When |
|---|---|---|---|
| whytestocks: $ATRC News Article - AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare | whytestocks | investorshangout | 02/17/2023 1:40:52 PM |
| whytestocks: $ATRC News Article - AtriCure to Participate in the 41st Annual J.P. Morgan Healthcare | whytestocks | investorshangout | 12/20/2022 4:50:46 PM |
| whytestocks: $ATRC News Article - AtriCure Reports Preliminary Results for Fourth Quarter and Full Y | whytestocks | investorshangout | 01/10/2022 5:45:48 PM |
| whytestocks: $ATRC News Article - AtriCure, inc (ATRC) Q3 2021 Earnings Call Transcript | whytestocks | investorshangout | 11/04/2021 5:30:52 PM |
| whytestocks: $ATRC News Article - AtriCure's EPi-Sense System Approved by FDA for Treatment of Long- | whytestocks | investorshangout | 04/29/2021 12:35:51 PM |
Ad
-
Worldwide revenue of $100.9 million – an increase of 19.4% year over year U.S. revenue of $84.9 million – an increase of 19.1% year over year International revenue of $16.0 million – an increase of 20.7% year over year Net loss of $5.1 million – an improvem...
-
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release second quarter 2023 financial results on Tuesday, July 2...
-
Worldwide revenue of $93.5 million – an increase of 25.4% year over year U.S. revenue of $78.2 million – an increase of 25.6% year over year International revenue of $15.3 million – an increase of 24.4% year over year Net loss of $6.5 million – an improveme...